(19)
(11) EP 3 016 669 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.04.2021 Bulletin 2021/16

(45) Mention of the grant of the patent:
31.03.2021 Bulletin 2021/13

(21) Application number: 14747997.6

(22) Date of filing: 03.07.2014
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
A61P 3/00(2006.01)
 A61K 35/74(2015.01)
A61P 3/10(2006.01)
(86) International application number:
PCT/SE2014/050848
(87) International publication number:
WO 2015/002604 (08.01.2015 Gazette 2015/01)

(54)

SECRETAGOGUES DERIVED FROM OXALOBACTER FORMIGENES

VON OXALOBACTER FORMIGENENS ABGELEITETE SEKRETAGOGA

SÉCRÉTAGOGUES DÉRIVÉS D'OXALOBACTER FORMIGENES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 03.07.2013 WO PCT/SE2013/050875

(43) Date of publication of application:
11.05.2016 Bulletin 2016/19

(73) Proprietor: OxThera Intellectual Property AB
111 39 Stockholm (SE)

(72) Inventors:
  • LINDNER, Elisabeth
    S-120 31 Stockholm (SE)
  • COWLEY, Helena
    Gainesville, Florida 32608 (US)
  • COWLEY, Aaron
    Gainesville, Florida 32608 (US)
  • ÅKERMAN, Maria
    191 35 Sollentuna (SE)

(74) Representative: Brann AB 
P.O. Box 3690 Drottninggatan 27
103 59 Stockholm
103 59 Stockholm (SE)


(56) References cited: : 
WO-A2-2005/097176
US-A1- 2004 234 514
US-A1- 2007 178 070
 WO-A2-2009/134339
US-A1- 2005 232 901
US-A1- 2008 038 246
   
  • B. HOPPE ET AL: "Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 26, no. 11, 1 November 2011 (2011-11-01), pages 3609-3615, XP055076654, ISSN: 0931-0509, DOI: 10.1093/ndt/gfr107
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).